



SN-US035209

**PATENT** 

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Shinpei OKAJIMA

Serial No.

10/765,997

Filed: January 29, 2004

For: BICYCLE RIM

Patent Art Unit: 3617

Examiner: Jason R. BELLINGER

AMENDMENT AFTER FINAL REJECTION

#### THE ASSISTANT COMMISSIONER FOR PATENTS

Sir:

Transmitted herewith is an Amendment in the above-identified application:

[X] No additional fee is required.

The fee has been calculated as shown below:

	CLAIMS		SMALL ENTITY	OTHER THAN A SMALL ENTITY
REMAINING	HIGHEST NO.			
AFTER	<b>PREVIOUSLY</b>	PRESENT	ADDIT.	ADDIT.
<b>AMENDMENT</b>	PAID FOR	EXTRA	RATE FEE	RATE FEE
TOTAL 20	- 20 =	0	x 25 =	x 50 = \$
INDEP 3	- 3 =	0	x 100 = \$	x 200 = \$
[ ] 1ST PRESENTAT	TION OF MULT. DE	P. CLAIM	+ 180 = \$	+ 360 = \$
			TOTAL \$	TOTAL \$

- [X] The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1836. A duplicate copy of this sheet is attached.
  - [X] Any additional excess claim fees under 37 C.F.R. 1.16.
  - [X] Any additional patent application processing fees under 37 C.F.R. 1.17.

Dated: September 6, 2005

David J. McCrosky Reg. No. 56,232

SHINJYU GLOBAL IP COUNSELORS, LLP 1233 Twentieth Street, NW, Suite 700 Washington, DC 20036 (202) 293-0444

G:\09-SEP05-KK\SN-US035209 Amendment Cover.doc

### SN-US035209

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Shinpei OKAJIMA

Serial No.

10/765,997

Filed: January 29, 2004

For: BICYCLE RIM



Patent Art Unit: 3617

Examiner: Jason R. BELLINGER

AMENDMENT AFTER FINAL REJECTION

# AMENDMENT UNDER 37 CFR § 1.116

Assistant Commissioner of Patents Washington, DC 20231

Sir:

In response to the July 13, 2005 Office Action, please amend the above-identified patent application as follows:

Amendments to the Claims are reflected in the <u>Listing of Claims</u>, which begins on page 2 of this paper. Claims 1-20 are pending, with claims 1, 2 and 16 being the only independent claims.

Remarks/Arguments begin on page 9 of this paper.